Literature DB >> 18708617

Drug delivery to posterior intraocular tissues: third Annual ARVO/Pfizer Ophthalmics Research Institute Conference.

Henry F Edelhauser1, Jeffrey H Boatright, John M Nickerson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18708617      PMCID： PMC2633627          DOI： 10.1167/iovs.08-1904

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN： 0146-0404            Impact factor:   4.799


× No keyword cloud information.
  83 in total

1.  Association of the HTRA1 -625G>A promoter gene polymorphism with exudative age-related macular degeneration in a Central European population.

Authors:  Martin Weger; Wilfried Renner; Iris Steinbrugger; Katharina Köfer; Andreas Wedrich; Andrea Groselj-Strele; Yosuf El-Shabrawi; Otto Schmut; Anton Haas
Journal:  Mol Vis       Date:  2007-07-24       Impact factor: 2.367

Review 2.  Photodynamic therapy and combination treatments.

Authors:  Sophia Pachydaki; Lucia Sobrin; Joan W Miller
Journal:  Int Ophthalmol Clin       Date:  2007

3.  Intraocular nanoparticle drug delivery: a pilot study using an aerosol during pars plana vitrectomy.

Authors:  Guifang Zhang; Xiao Feng; Kathy Wabner; Chris Fandrey; Amir Naqwi; Timothy Wiedmann; Timothy W Olsen
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-11       Impact factor: 4.799

4.  Loss of ER retention and sequestration of the wild-type ELOVL4 by Stargardt disease dominant negative mutants.

Authors:  Goutam Karan; Zhenglin Yang; Kimberly Howes; Yu Zhao; Yali Chen; D Josh Cameron; Yin Lin; Erik Pearson; Kang Zhang
Journal:  Mol Vis       Date:  2005-08-30       Impact factor: 2.367

5.  Stargardt-like macular dystrophy protein ELOVL4 exerts a dominant negative effect by recruiting wild-type protein into aggresomes.

Authors:  Vidyullatha Vasireddy; Camasamudram Vijayasarathy; Jibiao Huang; Xiaofei F Wang; Monica M Jablonski; Howard R Petty; Paul A Sieving; Radha Ayyagari
Journal:  Mol Vis       Date:  2005-08-30       Impact factor: 2.367

6.  In vitro sustained human transscleral drug delivery of fluorescein-labeled dexamethasone and methotrexate with fibrin sealant.

Authors:  Lars P J Cruysberg; Rudy M M A Nuijts; Jake A Gilbert; Dayle H Geroski; Fred Hendrikse; Henry F Edelhauser
Journal:  Curr Eye Res       Date:  2005-08       Impact factor: 2.424

7.  Coated microneedles for drug delivery to the eye.

Authors:  Jason Jiang; Harvinder S Gill; Deepta Ghate; Bernard E McCarey; Samir R Patel; Henry F Edelhauser; Mark R Prausnitz
Journal:  Invest Ophthalmol Vis Sci       Date:  2007-09       Impact factor: 4.799

8.  HTRA1 promoter polymorphism predisposes Japanese to age-related macular degeneration.

Authors:  Tsunehiko Yoshida; Andrew DeWan; Hong Zhang; Ryosuke Sakamoto; Haru Okamoto; Masayoshi Minami; Minoru Obazawa; Atsushi Mizota; Minoru Tanaka; Yoshihiro Saito; Ikue Takagi; Josephine Hoh; Takeshi Iwata
Journal:  Mol Vis       Date:  2007-04-04       Impact factor: 2.367

Review 9.  An update on the genetics of age-related macular degeneration.

Authors:  Hendrik P N Scholl; Monika Fleckenstein; Peter Charbel Issa; Claudia Keilhauer; Frank G Holz; Bernhard H F Weber
Journal:  Mol Vis       Date:  2007-02-07       Impact factor: 2.367

10.  Retinal pathology and skin barrier defect in mice carrying a Stargardt disease-3 mutation in elongase of very long chain fatty acids-4.

Authors:  Anne McMahon; Igor A Butovich; Nathan L Mata; Martin Klein; Robert Ritter; James Richardson; David G Birch; Albert O Edwards; Wojciech Kedzierski
Journal:  Mol Vis       Date:  2007-02-26       Impact factor: 2.367
View more
  5 in total

1.  Ophthalmic drug delivery systems for the treatment of retinal diseases: basic research to clinical applications.

Authors:  Henry F Edelhauser; Cheryl L Rowe-Rendleman; Michael R Robinson; Daniel G Dawson; Gerald J Chader; Hans E Grossniklaus; Kay D Rittenhouse; Clive G Wilson; David A Weber; Baruch D Kuppermann; Karl G Csaky; Timothy W Olsen; Uday B Kompella; V Michael Holers; Gregory S Hageman; Brian C Gilger; Peter A Campochiaro; Scott M Whitcup; Wai T Wong
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-11       Impact factor: 4.799

Review 2.  Drug and gene delivery to the back of the eye: from bench to bedside.

Authors:  Cheryl L Rowe-Rendleman; Shelley A Durazo; Uday B Kompella; Kay D Rittenhouse; Adriana Di Polo; Alan L Weiner; Hans E Grossniklaus; Muna I Naash; Alfred S Lewin; Alan Horsager; Henry F Edelhauser
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-28       Impact factor: 4.799

Review 3.  Ocular delivery of proteins and peptides: Challenges and novel formulation approaches.

Authors:  Abhirup Mandal; Dhananjay Pal; Vibhuti Agrahari; Hoang My Trinh; Mary Joseph; Ashim K Mitra
Journal:  Adv Drug Deliv Rev       Date:  2018-01-13       Impact factor: 15.470

4.  Drug delivery to the posterior segment of the eye for pharmacologic therapy.

Authors:  Shalin S Shah; Lori Vidal Denham; Jasmine R Elison; Partha S Bhattacharjee; Christian Clement; Tashfin Huq; James M Hill
Journal:  Expert Rev Ophthalmol       Date:  2010-02-01

5.  Noninvasive, in vivo assessment of mouse retinal structure using optical coherence tomography.

Authors:  M Dominik Fischer; Gesine Huber; Susanne C Beck; Naoyuki Tanimoto; Regine Muehlfriedel; Edda Fahl; Christian Grimm; Andreas Wenzel; Charlotte E Remé; Serge A van de Pavert; Jan Wijnholds; Marek Pacal; Rod Bremner; Mathias W Seeliger
Journal:  PLoS One       Date:  2009-10-19       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.